Recruiting
Phase 2

\[18F\]FETrp

Sponsor:

Barbara Ann Karmanos Cancer Institute

Code:

NCT07735819

Conditions

Low Grade Glioma

Glioblastoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Minocycline 200mg/day

[18F]FETrp PET/CT

Study Details

Brief summary:

The goal of this clinical trial is to evaluate Positron emission tomography/computed tomography (PET/CT) imaging with the radiotracer 1-(2-\[18F\]fluoroethyl)-l-tryptophan (\[18F\]FETrp) in patients diagnosed with a glioma. This study has 3 aims:

  • to assess if the \[18F\]FETrp PET/CT can outperform Magnetic Resonance Imaging (MRI) by providing a better treatment target volume in newly diagnosed Stage 4 glioma patients
  • better differentiate tumor progression from radiation induced MRI changes in post treatment stage 4 gliomas
  • by giving a drug that can inhibit a pathway to allow objective assessment of treatment effects in low grade gliomas

Conditions

Low Grade Glioma

Glioblastoma

Study ID

NCT07735819

Start date

Nov, 2026

Status verified date

Nov, 2026

Completion date

Jun 30, 2031

Anticipated

Primary completion date

Jun 30, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

FOR ARMS 1-3

Inclusion Criteria:

  • Age =18 years.
  • Patient is able to lie in the PET/CT scanner for at least 60 minutes while undergoing scanning.
  • Patient is willing and able to review, understand, and provide written consent for the study procedures and indicates that they are aware of the investigational nature of this study.

Exclusion Criteria:

  • Patients who are pregnant or lactating are excluded. Premenopausal women (defined per institutional guidelines) must have a negative pregnancy test (urine or serum) within 7 days of the PET scan.
  • Severe increased intracranial pressure, status epilepticus, or other severe or progressing clinical symptoms requiring urgent intervention in the opinion of the treating
  • Karnofsky performance score <60, as determined by one of the clinician co- investigators.

ADDITIONAL CRITERIA FOR ARM 1:

Inclusion Criteria:

  • Histopathology/cytopathological diagnosis of a glioblastoma without a history of radiation.
  • The tumor is deemed amenable for radiation treatment (pre-radiation planning MRI can be done before or after the PET scan).

ADDITIONAL CRITERIA FOR ARM 2:

Inclusion Criteria:

  • Previous histopathology/cytopathological diagnosis of glioblastoma.
  • History of glioma radiation.
  • Presence of a new or progressing enhancing brain lesion on follow-up clinical MRI suspicious for post-radiation glioma progression or late radiation-induced MRI changes (i.e., radiation injury), at least 7 mm in bidirectional diameter.
  • The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks of the planned PET scan.

ADDITIONAL CRITERIA FOR ARM 3

Inclusion Criteria:

  • MRI diagnosis of a brain tumor, previously verified to be a low-grade (WHO grade 2, IDH (isocitrate dehydrogenase) mutant glioma, based on histopathology from biopsy or resection.
  • The detected mass on the most recent clinical MRI is at least 7 mm in bidirectional diameter (i.e., twice the PET scanner resolution).
  • The tumor does not require urgent (within 1 month) resection, steroid treatment, or radiation.
  • The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks.
  • Patient agrees to have a baseline and follow-up PET/CT scan (approximately 1 month later) and interval oral treatment with 200mg/day minocycline.
  • Due to planned minocycline treatment, patients will need to have adequate renal function

Exclusion Criteria:

  • Active connective tissue disorders, such as lupus or scleroderma.
  • History of allergic reaction to minocycline or any tetracyclines.
  • Ongoing treatment with warfarin with INR > 1.5.
  • History of colitis during antibiotics treatment.
  • Concomitant medications or supplements taken that interact with minocycline and cannot be safely held or adjusted

Study Design

Enrollment

61 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: [18F]FETrp PET/CT in newly diagnosed grade 4 glioma prior to radiation

Arm 1. \[18F\]FETrp PET prior to radiotherapy in newly diagnosed grade 4 glioblastoma to provide a better treatment target volume

experimental: [18F]FETrp PET/CT in previously treated gliomas with post radiation progression

Arm 2. \[18F\]FETrp PET to differentiate post-treatment glioma progression from radiation-induced MRI changes

experimental: [18F]FETrp PET/CT pre and post Minocycline 200mg/day

Arm 3. Minocycline orally 200mg/day administered between the first \[18F\]FETrp PET scan and the month follow up \[18F\]FETrp scan to determine if pharmacologic inhibition of the kynurenine pathway will reduce tumoral tryptophan metabolic rates in low-grade gliomas

Interventions

Minocycline 200mg/day

Minocycline 200mg orally daily to start within 14 days of the first \[18F\]FETrp PET/CT and taken until the second \[18F\]FETrp PET/CT obtained 25-44 days after the start of the Minocycline in Arm 3

[18F]FETrp PET/CT

\[18F\]FETrp PET/CT used in all three arms

Primary outcome measure

  • Difference Between Dice Similarity Coefficients (DSC) of Position Emission Tomography (PET) High K Tumor Volume and DSC of MRI-based Tumor Volume (d-PETk-MRI) in Arm 1 [ Time Frame: From the time of the pre-radiotherapy scans (Baseline) up to tumor progression or study completion, assessed at a maximum follow-up of 2 years. ]
  • Sensitivity of [18F]FETrp PET Kinetic Influx Rate (PETk) with a predefined L/C ratio threshold of 1.60 in differentiating Tumor Progression from Radiation Injury in Arm 2 [ Time Frame: From the date of the [18F]FETrp PET/CT scan up to the date of confirmed ground truth designation via histopathology or serial MRI follow-up, assessed over a maximum period of 1 year per participant. ]
  • Change in [18F]FETrp Kinetic Influx Rate (K) Values Following One Month of Standard of Care Plus Indoleamine 2,3-dioxygenase (IDO) Inhibitor Treatment (d-PETK) in Arm 3 [ Time Frame: From Baseline (within 2 weeks prior to treatment initiation) to 1-month post-treatment (30 days ± 5 days, up to 44 days). ]

Central Contacts and Locations

Central contacts

Csaba Juhasz, M.D.,Ph.D.

313-966-5136csaba.juhasz@wayne.edu

Locations

Karmanos Cancer Institute

Recruiting

Detroit, Michigan, United States, 48201

Contacts

Csaba Juhasz, M.D., Ph.D

1-800-527-6266

More Information

Sponsor

Barbara Ann Karmanos Cancer Institute

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.